International Journal of Clinical Research

Objective To explore the clinical effect of early combined intensive statin therapy in the treatment of cerebral infarction. Methods A total of 100 patients with cerebral infarction admitted to our hospital from January 2023 to January 2024 were selected as the research objects. They were randomly divided into the observation group (treated with early combined intensive statin therapy) and the control group (treated with early conventional therapy). The carotid atherosclerosis, plasma lipoprotein-associated phospholipase A2 (Lp-PLA2), blood lipid levels before and after treatment, and treatment effects were compared between the two groups. Results The carotid atherosclerosis indicators [plaque Crouse score (3.05±0.32) points, carotid artery diameter (7.89±1.54) mm, carotid intima-media thickness (0.89±0.51) mm], plasma Lp-PLA2 level [(163.12±12.59) μg/L], and blood lipid indicators [high-density lipoprotein cholesterol (1.72±0.32) mmol/L, low-density lipoprotein cholesterol (1.67±0.14) mmol/L, total cholesterol (4.02±0.95) mmol/L, triglycerides (1.05±0.28) mmol/L] in the observation group were all better than those in the control group. The treatment effective rate of the observation group (94.0%) was higher than that of the control group (P<0.05). Conclusion The clinical effect of early combined intensive statin therapy in the treatment of cerebral infarction is significant, which is worthy of extensive promotion and application.

Early treatment; Intensive statin therapy; Cerebral infarction; Clinical effect